Statins for women with polycystic ovary syndrome not actively trying to conceive (Q24236132)

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Cardiovascular consequences of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

The prevalence and features of the polycystic ovary syndrome in an unselected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of the 17 alpha-hydroxylase:C-17,20-lyase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

The Role of Lipoproteins in Steroidogenesis and Cholesterol Metabolism in Steroidogenic Glands*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Statins in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Impaired carotid viscoelastic properties in women with polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Treatment of hirsutism and acne in hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Polycystic ovarian syndrome: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Cellular antioxidant effects of atorvastatin in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Long-term health consequences of PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

ACOG practice bulletin. Polycycstic ovary syndrome. Number 41, December 2002

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Insulin-like growth factor I enhancement of steroidogenesis by bovine granulosa cells and thecal cells: dependence on de novo cholesterol synthesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008565.PUB2

7 January 2021

10.1002/14651858.CD008565.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

715566

OpenCitations bibliographic resource ID

715566

1 reference